Advanced treatment in high-grade gliomas

Area of Science:

• Neuro-oncology
• Brain Tumor Research
• Molecular Pathology

Background:

• Gliomas represent a significant challenge in neuro-oncology due to their high incidence, poor prognosis, and difficulties in surgical resection.
• Current treatments for high-grade gliomas often yield unsatisfactory efficacy and are associated with high recurrence rates.
• Factors influencing glioma recurrence include patient age, surgical intervention, radiotherapy, chemotherapy, and tumor molecular pathology.

Purpose of the Study:

• To review the current understanding of high-grade glioma pathogenesis and treatment challenges.
• To explore the potential of novel therapeutic strategies for recurrent high-grade gliomas.
• To highlight advancements in molecular biology and their impact on targeted therapies.

Main Methods:

• Literature review of studies on glioma treatment and recurrence.
• Analysis of factors impacting high-grade glioma outcomes.
• Examination of emerging therapeutic modalities in neuro-oncology.

Main Results:

• Traditional treatments for high-grade gliomas demonstrate limited efficacy, particularly for recurrent cases.
• Molecular biology advancements provide deeper insights into glioma pathogenesis, driving interest in molecular targeted therapy.
• A growing number of diverse treatment options are becoming available for recurrent high-grade gliomas.

Conclusions:

• The development of molecular targeted therapy is a significant advancement in glioma treatment.
• Emerging therapies including oncolytic virus therapy, stem cell therapy, immunotherapy, and electric field therapy show promise.
• These novel approaches are expected to improve the clinical outlook for patients with recurrent high-grade gliomas.